Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by MindMed

MindMed to Participate at May Investor Conferences
From MindMed
Via Business Wire
Tickers MNMD
MindMed Reports First Quarter 2024 Financial Results and Business Updates
From MindMed
Via Business Wire
Tickers MNMD
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
From MindMed
Via Business Wire
Tickers MNMD
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
From MindMed
Via Business Wire
Tickers MNMD
MindMed to Present at Upcoming May Medical Conferences
From MindMed
Via Business Wire
Tickers MNMD
MindMed Announces Voluntary Delisting from Cboe Canada
From MindMed
Via Business Wire
Tickers MNMD
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
From MindMed
Via Business Wire
Tickers MNMD
MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120
From MindMed
Via Business Wire
Tickers MNMD
MindMed Reports 2023 Financial Results and Business Updates
From MindMed
Via Business Wire
Tickers MNMD
MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update
From MindMed
Via Business Wire
Tickers MNMD
MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference
From MindMed
Via Business Wire
Tickers MNMD
MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
From MindMed
Via Business Wire
Tickers MNMD
MindMed Reports Second Quarter 2023 Financial Results and Business Highlights
From MindMed
Via Business Wire
Tickers MNMD
MindMed Urges Shareholders to Vote TODAY for Company Nominees Ahead of June 13th Deadline
From MindMed
Via Business Wire
Tickers MNMD
Leading Proxy Advisory Firm ISS Recommends MindMed Shareholders Vote FOR All Six Company Nominees
From MindMed
Via Business Wire
Tickers MNMD
MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting
From MindMed
Via Business Wire
Tickers MNMD
MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
From MindMed
Via Business Wire
Tickers MNMD
MindMed Reports First Quarter 2023 Financial Results and Business Highlights
From MindMed
Via Business Wire
Tickers MNMD
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy
From MindMed
Via Business Wire
Tickers MNMD
MindMed to Participate in May Investor Conferences
From MindMed
Via Business Wire
Tickers MNMD
MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting
From MindMed
Via Business Wire
Tickers MNMD
MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)
From MindMed
Via Business Wire
Tickers MNMD
MindMed Appoints Mark R. Sullivan as Chief Legal Officer and Corporate Secretary
From MindMed
Via Business Wire
Tickers MNMD
MindMed Reports Full Year 2022 Financial Results and Business Highlights
From MindMed
Via Business Wire
Tickers MNMD
MindMed to Participate in March Investor Conferences
From MindMed
Via Business Wire
Tickers MNMD
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.